- Home
- ARR vs AUPH Comparison
ARR vs AUPH Comparison
Compare ARR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARR
- AUPH
- Stock Information
- Founded
- ARR 2008
- AUPH 1993
- Country
- ARR United States
- AUPH Canada
- Employees
- ARR N/A
- AUPH N/A
- Industry
- ARR Real Estate Investment Trusts
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- ARR Real Estate
- AUPH Health Care
- Exchange
- ARR Nasdaq
- AUPH Nasdaq
- Market Cap
- ARR 1.4B
- AUPH 1.4B
- IPO Year
- ARR N/A
- AUPH 1999
- Fundamental
- Price
- ARR $15.32
- AUPH $11.99
- Analyst Decision
- ARR Hold
- AUPH Strong Buy
- Analyst Count
- ARR 5
- AUPH 4
- Target Price
- ARR $16.00
- AUPH $12.25
- AVG Volume (30 Days)
- ARR 4.8M
- AUPH 2.2M
- Earning Date
- ARR 10-22-2025
- AUPH 07-31-2025
- Dividend Yield
- ARR 18.81%
- AUPH N/A
- EPS Growth
- ARR N/A
- AUPH N/A
- EPS
- ARR N/A
- AUPH 0.42
- Revenue
- ARR $20,589,000.00
- AUPH $260,111,000.00
- Revenue This Year
- ARR $378.40
- AUPH $16.92
- Revenue Next Year
- ARR $40.72
- AUPH $14.29
- P/E Ratio
- ARR N/A
- AUPH $28.52
- Revenue Growth
- ARR N/A
- AUPH 25.59
- 52 Week Low
- ARR $13.18
- AUPH $6.42
- 52 Week High
- ARR $21.08
- AUPH $12.53
- Technical
- Relative Strength Index (RSI)
- ARR 45.85
- AUPH 66.61
- Support Level
- ARR $14.95
- AUPH $11.83
- Resistance Level
- ARR $15.26
- AUPH $12.46
- Average True Range (ATR)
- ARR 0.23
- AUPH 0.39
- MACD
- ARR 0.06
- AUPH -0.11
- Stochastic Oscillator
- ARR 84.12
- AUPH 60.00
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.